TearClear Appoints Robert Bailey to Board of Directors

Bailey's executive experience in the Ophthalmology industry further strengthens the organization

TearClear announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors. Mr. Bailey brings over two decades of leadership experience in the Ophthalmology industry having served on the executive teams as General Counsel/Chief Legal Officer for Allergan and Bausch + Lomb.

“We welcome Bob’s leadership, judgment and industry expertise to our Board” said TearClear Chief Executive Officer Robert Dempsey. “His extensive M&A and Public Markets experience will be a tremendous asset as we seek to advance the mission of TearClear.”

“TearClear represents a brilliant and versatile platform that addresses patient and physician unmet needs,” Bailey said. “I know and respect the TearClear management team, both as former colleagues and competitors, and I look forward to serving with them to bring this important innovation to market.”

About Preservative Free

Preservatives, such as benzalkonium chloride (BAK), are necessary in ophthalmic solutions to maintain sterility. However, on the ocular surface, they have been reported to be associated with adverse effects like hyperemia, tear film instability and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long term deleterious effects on the eye are reduced. TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions.